Cargando…

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration

BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mantel, Irmela, Zola, Marta, Mir, Olivier, Gaillard, Raphael, Behar-Cohen, Francine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582817/ https://www.ncbi.nlm.nih.gov/pubmed/30030393 http://dx.doi.org/10.1136/bjophthalmol-2018-312318

Ejemplares similares

Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
por: Zola, Marta, et al.
Publicado: (2020)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
por: Mantel, Irmela, et al.
Publicado: (2019)

Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study
por: Gigon, Anthony, et al.
Publicado: (2022)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
por: Zhao, Min, et al.
Publicado: (2019)

EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE
por: Kowalczuk, Laura, et al.
Publicado: (2017)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration
por: Montesel, Andrea, et al.
Publicado: (2022)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment
por: Mantel, Irmela, et al.
Publicado: (2020)

Automated Quantification of Pathological Fluids in Neovascular Age-Related Macular Degeneration, and Its Repeatability Using Deep Learning
por: Mantel, Irmela, et al.
Publicado: (2021)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
por: Chakravarthy, Usha, et al.
Publicado: (2020)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration
por: Qiu, Fangfang, et al.
Publicado: (2017)

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008)

Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature
por: Dirani, Ali, et al.
Publicado: (2014)

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
por: Kovacs, Attila, et al.
Publicado: (2018)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
por: Cho, Soo Chang, et al.
Publicado: (2023)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Personalized Atrophy Risk Mapping in Age-Related Macular Degeneration
por: Gigon, Anthony, et al.
Publicado: (2021)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
por: Khachigian, Levon M., et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

The effect of intravitreal bevacizumab (Avastin(®)) on ocular pulse amplitude in neovascular age-related macular degeneration
por: Rechtman, Ehud, et al.
Publicado: (2011)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography
por: Derradji, Yasmine, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aicgq1s1i1fmlb064q9cvqolkk